BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Asuragen, Inc. Signs Armored RNA(R) Licensing Agreement with Focus Diagnostics, Inc.


9/9/2008 6:51:21 AM

AUSTIN, Texas & CYPRESS, Calif.--(BUSINESS WIRE)--Asuragen, Inc., announces that it has granted Focus Diagnostics, Inc., the infectious disease diagnostics company of Quest Diagnostics, non-exclusive worldwide rights to incorporate Armored RNA® technology into its in vitro molecular diagnostics products. Under the terms of the Agreement, Asuragen will develop and supply reagents for Focus Diagnostics in Asuragen’s QSR-compliant manufacturing facility. Additional terms were not disclosed.

Armored RNA® is a technology jointly invented and developed by Asuragen and Cenetron Diagnostics for the packaging of RNA or DNA in bacteriophage coat proteins for protection and stabilization. The Armored RNA® technology encapsulates RNA standards in a protective protein coat, assuring their integrity during long-term storage. It also “armors” the RNA standard against the hazards of nucleases in patient samples. RNA standards are essential to quantitative molecular diagnostic assays, and maintaining their integrity is crucial to obtaining accurate, reliable results. Asuragen recently released Armored RNA® Quant™, the next generation of quantitative standards. Armored RNA® Quant™ contains a precisely quantified copy number of a specific target and is referenced to a National Institute of Standards & Technology (NIST) traceable phosphate standard. Armored RNA® Quant™ can be used to construct standard curves for quantitation and as an internal quantitative sample calibrator for infectious disease and oncology testing.

“We’re pleased Focus Diagnostics has chosen to incorporate Armored RNA® into its molecular diagnostic assays. This Agreement reinforces the continued evolution of Armored RNA® standards and controls into an industry standard,” said Matt Winkler, Ph.D., CEO and CSO, Asuragen, Inc.

About Asuragen, Inc.

Asuragen is a fully integrated molecular diagnostics company focused on molecular oncology and early detection of cancer with emphasis on microRNA. Asuragen’s current diagnostic product portfolio consists of Signature® Genetic Testing and Oncology Testing products as well as industry leading controls and standards engineered with its patented Armored RNA® technology. Asuragen is empowered with a high level of scientific expertise and assay development along with a well developed business infrastructure, GLP and clinical laboratory testing services and an established cGMP manufacturing facility that allow it to span the spectrum of discovery, testing, production and commercialization. Asuragen is dedicated to developing new technologies that will become cutting edge clinical products. More information is available at the Company’s website: www.asuragen.com.

About Cenetron Diagnostics

Cenetron Diagnostics is a clinical reference laboratory that specializes in molecular diagnosis of infectious diseases and genotyping assays and supports pharmaceutical industry-sponsored clinical trials.

Contact:

Asuragen, Inc., Austin Cindy WalkerPeach, Ph.D., 512-681-5200 Director, Corporate Business Development cwalkerpeach@asuragen.com or Lori Brisbin, 512-681-5200 Global Director of Sales and Marketing lbrisbin@asuragen.com www.asuragen.com or Quest Diagnostics, parent company of Focus Diagnostics Wendy Bost, 973-520-2850 External Communications Wendy.H.Bost@questdiagnostics.com www.focusdx.com

Source: Asuragen, Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES